Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stargardt Patient Treated With Retinal Pigment Epithelial Cells

Published: Friday, July 13, 2012
Last Updated: Friday, July 13, 2012
Bookmark and Share
Patient injected with 100,000 RPE cells at Wills Eye Institute.

Advanced Cell Technology, Inc. announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).

The surgery was performed on Wednesday, July 11 at Wills Eye Institute in Philadelphia, by a surgical team lead by Carl D. Regillo, MD, FACS, director of the Wills Eye Clinical Retina Research Unit, attending surgeon in the Wills Eye Retina Service at the Wills Eye Institute, and professor of ophthalmology at Thomas Jefferson University. In keeping with trial protocol, the patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with the 50,000 cell dose used in the three patients of the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.

"It is very gratifying to have second cohort, higher-dosage patient treatment underway in our U.S. clinical trial for SMD," commented Gary Rabin, chairman and CEO of ACT. "We are also pleased to be working with Dr. Regillo and his team at Wills Eye Institute, a truly first-class institution that is ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report."

Initiated in July of last year, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. As part of its RPE clinical program, the company is concurrently conducting a clinical trial for dry age-related macular degeneration and second trial for SMD in the United Kingdom.

"Doubling the cell dosage marks an important milestone in our clinical programs," said Robert Lanza, MD, ACT's chief scientific officer. "We look forward to continued progress and safety findings in the coming months, in both our U.S. and European trials."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Positive Safety Results for Macular Degeneration Treatment
Phase 1/2 clinical trials of RPE cells for the treatment of dry age-related macular degeneration and Stargardt’s macular degeneration show positive long term safety results and signs of visual improvement.
Thursday, October 16, 2014
ACT Issued Broad Patent for Human RPE Cells
New Australian patent covers human RPE cells made from range of pluripotent stem cells, including both embryonic stem cells and iPS cells.
Tuesday, July 31, 2012
ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration
Third Stargardt's patient in EU trial treated with RPE cells derived from human embryonic Stem Cells at Moorfields Eye Hospital in London.
Monday, July 30, 2012
ACT Announces Europe's First Human Embryonic Stem Cell Transplant in Patient with Stargardt's Disease
Moorfields Eye Hospital in London initiates clinical trial using hESC-derived RPE cells.
Monday, January 23, 2012
Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial
Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells.
Tuesday, January 17, 2012
Advanced Cell Technology's CEO Says Markets Are Just Starting to Appreciate the Significance of Their Stem Cell Derived Treatments
Several key announcements have pushed Advanced Cell Technology's stock from just under a nickel in late November to an intraday high of $.20 during Wednesday's session and volume has made it apparent that a growing crowd of day traders momentum players have now joined biotech investors in cheering on the small biotech.
Friday, December 10, 2010
ACT Receives FDA Clearance for the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
Company to commence a Phase I/II clinical trial at multiple centers.
Wednesday, November 24, 2010
NIH Approves Advanced Cell Technology’s Stem Cell Line for Federal Funding
Access to federal funding could accelerate clinical development.
Monday, June 14, 2010
ACT Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease
The Phase I/II trial will be an open-label study designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation.
Thursday, November 26, 2009
Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA
Advanced Cell Technology files IND with FDA for first human clinical trial using embryonic stem cells to treat eye disease.
Monday, November 23, 2009
Functional Vasculature Generated from Advanced Cell Technology’s Human Embryonic Stem Cells
Hemangioblasts form multilayered blood vessels with functional smooth muscle; could provide an inexhaustible source of cells to treat vascular disease.
Tuesday, January 06, 2009
Advanced Cell Technology and CHA Biotech Form new International Stem Cell Company
The new company; Allied Cell Technology; will develop human blood cells and other clinical therapies based on ACTC’s hemangioblast cell technology.
Tuesday, December 02, 2008
Clinical-Scale Generation of Functional Red Blood Cells from Human Embryonic Stem Cells
ACT reports that it is feasible to differentiate and mature hESCs into functional oxygen-carrying RBCs under conditions suitable for scale-up.
Wednesday, August 20, 2008
Advanced Cell Technology Demonstrates Generation of Functional Hepatocytes from Human Embryonic Stem Cells
The research signifies a step towards the efficient generation of hepatocytes for use in regenerative medicine and drug discovery.
Friday, February 22, 2008
Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines without the Destruction of Embryos
Breakthrough approach improves efficiency to levels reported in the conventional stem cell derivation techniques.
Friday, January 11, 2008
Scientific News
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Rapidly Generating Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
New Mechanism of Tuberculosis Infection
Researchers have identified a new infection mechanism of tuberculosis that could lead to a new therapeutic angle.
Modelling ALS Requires ‘Aged’ Stem Cells
Research suggests engineered cells are too ‘young’ to accurately model ALS and should be 'aged' to speed progress toward finding potential treatments.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
HIV Hides No Longer
Researchers are working to create proteins that clear HIV-infected cells in order to eliminate latent infection and dormancy.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!